Dissociation method of antigen in aluminum adjuvant absorption type novel coronavirus inactivated vaccine

A coronavirus, inactivated vaccine technology, used in the field of biopharmaceuticals

Active Publication Date: 2020-10-23
BEIJING BIOLOGICAL PROD INST CO LTD +1
View PDF16 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no relevant report on the dissociation method of the effective components of the aluminum adjuvant-adsorbed SARS-CoV-2 inactivated vaccine at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dissociation method of antigen in aluminum adjuvant absorption type novel coronavirus inactivated vaccine
  • Dissociation method of antigen in aluminum adjuvant absorption type novel coronavirus inactivated vaccine
  • Dissociation method of antigen in aluminum adjuvant absorption type novel coronavirus inactivated vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] This embodiment provides a method for dissociation of antigens in an aluminum adjuvant-adsorbed novel coronavirus inactivated vaccine, which specifically includes the following steps:

[0044] (1) Preparation of test samples and reference products of aluminum adjuvant-adsorbed novel coronavirus inactivated vaccine:

[0045] The sample to be tested for the aluminum adjuvant-adsorbed novel coronavirus inactivated vaccine is self-made (currently there is no commercial product). The preparation scheme is as follows: the virus stock solution of the novel coronavirus inactivated vaccine (in the detection index of the virus stock solution, the antigen content is 138U / ml, and the protein content is 215μg / ml) is diluted in proportion according to the target concentration of the prepared 8U / ml antigen, and then added with aluminum The adjuvant prepared the aluminum adjuvant adsorption type SARS-CoV-2 inactivated vaccine test sample with a final concentration of novel coronavirus ...

Embodiment 2

[0065] In this example, the results of antigen dissociation in SARS-CoV-2 inactivated vaccine samples with different quality attributes are provided, and the applicability of the dissociation method to different samples is investigated. Specifically include:

[0066] (1) Preparation of samples to be tested and reference products:

[0067] The preparation process of the sample to be tested is the same as in Example 1, and the concentration preparation is shown in Table 3, and the corresponding reference product is prepared, and the preparation method is the same as in Example 1.

[0068] (2) Preparation of desorbent composition: same as Example 1.

[0069] (3) Implementation process of the dissociation program: the same as in Example 1.

[0070] (4) The detection method of the antigen content in the novel coronavirus antigen desorption solution is the same as in Example 1, and see Table 3 for the specific dilution method.

[0071] Table 3 shows the detection results of SARS-...

Embodiment 3

[0077] This example provides the results of dissociation of antigens in SARS-CoV-2 inactivated vaccines using dissociation methods with different concentrations of desorbent compositions and different dissociation program parameter conditions, and investigates the applicability of the method to samples. Specifically include:

[0078] (1) Preparation of test sample and reference product: same as Example 1.

[0079] (2) Preparation of desorbent composition:

[0080] The final mass concentration of sucrose is 5%-10% (w / v).

[0081] The mass final concentration of magnesium chloride hexahydrate is 0.5%-1% (w / v).

[0082] 0.6mol / L Potassium Phosphate Buffer Preparation Method:

[0083] It is obtained by mixing 1mol / L potassium phosphate buffer solution and water for injection in proportion. Take the preparation of 10ml, 0.6mol / L potassium phosphate buffer solution as an example, measure 6ml, 1mol / L potassium phosphate buffer solution and 4ml water for injection, and after mixin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a dissociation method of an antigen in an aluminum adjuvant absorption type novel coronavirus inactivated vaccine. A desorption agent composition adopted by the method comprisescane sugar, magnesium chloride, potassium phosphate and polysorbate-80, wherein the dosage ratio of the cane sugar to the magnesium chloride to the potassium phosphate to the polysorbate-80 is (50-100)g: (2-6)g: (0.3-0.6)mol: (0.5-1)ml. Antigens in the aluminum adjuvant absorption type novel coronavirus inactivated vaccine are dissociated, a solution system can be stabilized, the immunocompetenceof the antigens can be protected, the absorption capacity of an aluminum adjuvant can be destroyed, and the antigens can be rapidly separated from the aluminum adjuvant, interference of an aluminum adjuvant on accurate quantification of the antigen is eliminated, the method can solve a problem of unstable biological structure of the new coronavirus epitope in the dissociation process, has the characteristics of good repeatability, high accuracy and strong specificity, and provides an important tool for evaluating the key quality attributes of the novel coronavirus inactivated vaccine.

Description

technical field [0001] The invention belongs to the field of biopharmaceuticals, in particular to a method for dissociating antigens in an aluminum adjuvant-adsorbed novel coronavirus (SARS-CoV-2) inactivated vaccine. Background technique [0002] The challenge of the global new crown epidemic is still severe, and my country is stepping up scientific research and product launch of the new crown vaccine. The new coronavirus (hereinafter referred to as "SARS-CoV-2") inactivated vaccine is a powerful shield against virus invasion, and its key component is the antigen associated with clinical effectiveness, which should be accurately quantified in the quality control process of the product to be able to Realize the function of evaluating product quality attributes. [0003] Existing studies believe that the new crown vaccine antigen is mainly composed of S protein, M protein, N protein, etc., which can only be detected by ELISA. At present, the SARS-CoV-2 inactivated vaccine t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/531G01N33/569
CPCG01N33/531G01N33/56983G01N2333/165G01N2469/10
Inventor 王辉于守智赵玉秀张越董圆刘英微李艳宋彦丽张征丽杨晓明
Owner BEIJING BIOLOGICAL PROD INST CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap